Feyi Olopade Ayodele on the Importance of Early Cancer Detection in a Value-Based Care System
With CancerIQ, we’re really going to be helping push population health into the oncology arena where we can hopefully predict and preempt this very costly and devastating disease well in advance, says Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Transcript How important is prevention through genetic testing for value-based care?
In a value-based care system, CancerIQ really is the model for that happening. In the realm of oncology in particular there are varying cancer types and we know it’s so expensive to treat once it becomes past a certain stage. CancerIQ really is on the forefront of detecting those early-onset aggressive cancers that tend to be hereditary and really trying to catch those early or reduce risk altogether. Another thing that’s unique about our company is that we really do work well with all types of providers from the oncologist who is identifying a hereditary cancer and needs it to drive the appropriate, most cost-effective treatment decision, to the [obstetrician/gynecologist] provider, who is really on the front lines making sure that patient’s going in for the right preventive service at the right time. With CancerIQ, we’re really going to be helping push population health into the oncology arena where we can hopefully predict and preempt this very costly and devastating disease well in advance.